Introduction
After secretion from alveolar type II cells, pulmonary surfactant traverses a thin aqueous layer where it accumulates in the subsurface space and adsorbs onto the air-liquid interface. Under normal conditions, the interfacial surfactant then lowers surface tension, thereby stabilizing airspaces [1] [2] [3] . The overall effect is to decrease the work of breathing during inspiration, to prevent alveolar collapse, and to maintain a reservoir of air in the lungs during expiration. Under some abnormal conditions, for example after lung injury from a variety of noxious agents (e.g., smoke, viral or bacterial pathogens), lung inflammation ensues with leakage of serum from capillaries into alveoli. Serum and other inflammatory constituents can inactivate surfactant by a number of mechanisms [4] . In particular, serum proteins adsorb to the air-liquid interface and inhibit surfactant accumulation resulting in impaired surface activity and gas exchange [5, 6] .
We and others have found that various ionic and non-ionic polymers such as hyaluronan (HA), chitosan, polyethylene glycol (PEG), dextran, as well as other substances like polymyxin can enhance surface activity of a number of surfactants in the presence of inactivating substances such as serum, albumin, or meconium either in vitro or in vivo [4, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] .
SP-B, a hydrophobic surfactant protein, promotes the bilayer to monolayer conversion of lipid vesicles, a process that leads to adsorption of surfactant from the subsurface space to the air liquid interface [17] [18] [19] , and also prevents inhibition of surface activity of surfactant lipid mixtures when inactivating substances are present [20] . When SP-B is inhibited or absent in surfactant, lung function is severely impaired [21, 22] . KL 4 was developed as a peptide analogue of SP-B. It is a positively charged 21-residue helical peptide composed of repetitions of a motif containing four hydrophobic leucines. In an investigational formulation, lucinactant, (Surfaxin®, Discovery Laboratories, Inc., Warrington, PA) KL 4 is formulated by the addition of KL 4 to dipalmitoyl phosphatidylcholine (DPPC), palmitoyl-oleyl phosphatidylglycerol (POPG) and palmitic acid. This formulation has been extensively studied in vitro, in vivo and in clinical trials. Although details of the KL 4 interaction with lipid structures remain under investigation [23] [24] [25] [26] , its ability to improve surface activity in vitro and its beneficial use in certain lung injuries are well established [27] [28] [29] [30] [31] . With these findings in mind, we have tested whether the results we observed when adding polymer to commercial exogenous surfactants derived from animals [11, 12] could be duplicated with lucinactant, a mixture of a synthetic peptide and simple lipids. To separate the effects of KL 4 vs. polymer, we carried out studies without KL 4 and with two concentrations of KL 4 in the presence and absence of PEG or HA.
Methods

Materials
Lucinactant containing 0.8 mg/ml KL 4 , 22.5 mg/ml DPPC, 7.5 mg/ ml POPG and 4 mg/ml palmitic acid plus formulations containing zero and 0.4 mg/ml KL 4 were supplied by Discovery Laboratories, Inc. Polyethylene glycol (PEG 10 kDa) and hyaluronan (HA 1240 kDa) were obtained from Sigma Aldrich (St. Louis, MO). Hyaluronan (HA 250 kDa) was obtained from GlycoMed Research, Inc. (Hastings-on-Hudson, NY). Serum with an approximate protein concentration of 70 mg/ml was obtained from adult, healthy, non-smoking volunteers as sanctioned by our institutional research review board. Prior work in our laboratory has found no differences in inhibitory capacity among sera from healthy volunteers, those with ARDS [32] , or with discarded serum obtained from infants requiring exchange transfusion (unpublished data).
Procedures
Before dilution, surfactant mixtures were: lipids (30 mg/ml); lipids with 0.4 mg/ml KL 4 and lipids with 0.8 mg/ml Kl 4 . These mixtures were diluted to 1.25 mg total lipids/ml with buffer containing 2.5 mM HEPES with 0.9% NaCl and 2.5 mM CaCl 2 adjusted to a pH of 7.0. After dilution, the mixtures are referred to as lipids, KL 4 0.4, or KL 4 0.8. Concentrations (w/v), and molecular weights of polymers used were those we found effective in previous studies; that is, PEG 10 kDa, 5%; or HA 250 kDa or 1240 kDa, 0.25% [8] [7, 12] . Dry polymers were combined with the diluted lipid mixtures at room temperature and dispersed by Vortex in 5-s bursts for 1-2 min until uniform in appearance. Serum, when used, was added last and mixed as above.
Mixtures were tested alone, or with added PEG or HA in the presence or absence of various concentrations of serum.
For these experiments, we used a modified pulsating bubble surfactometer whose strengths and limitations in assessing surface activity have been fully described [33] . The modification is to avoid leakage of surfactant film into the capillary opening to minimize differences in area that could affect the surface tension [34] . Samples were placed in 25 µl chambers from which a 0.4 mm radius bubble was drawn and surface tension of the static bubble was measured over 40 s. The bubble was then inflated and deflated at a rate of 20 times per minute between a radius of 0.4 and 0.55 mm while pressure was recorded. Surface tension was calculated by the Laplace formula: P = ST/r, (where ST is surface tension, P is the inflating pressure, and r is the bubble radius), assuming a spherical bubble shape. Sample chambers were maintained at 37°C during the measurements by means of a temperature-controlled water jacket. The device was calibrated by water manometer and by use of pure fluids with known surface tension.
Six indices of surface activity were recorded for the various surfactant mixtures and each mixture was measured five times with the results averaged: 6. An estimate of surface film compressibility after 5 min of bubble cycling obtained by calculating the percentage of surface area reduction from its maximum value required for surface tension to fall to 10 mN/m (A 10 ). A low value indicates that the surface film is relatively non-compressible. If surface tension did not fall to ≤10 mN/m after maximal surface compression (that is when the minimum bubble radius of 0.4 mm was reached), a limit of N47 was assigned, corresponding to the difference in area between maximum and minimum bubble sizes.
Sufficient serum was added to mixtures to increase the minimum surface tension after 5 min of cycling to values above 10 mN/m, which is used as the threshold for an effective surfactant [35] . Serum was added in increments of 350 µg serum protein/ml to a maximum concentration of 1400 µg/ml. The various mixtures were studied to determine the serum concentration above which inhibition occurred.
Analysis
The data are presented as means ± SEM. Measurements were analyzed by one way analysis of variance (ANOVA) using SigmaStat software (SPSS Science, Chicago, IL). Comparisons between pairs of groups were done using the Tukey test or the Kruskal-Wallis test when necessary to correct for multiple comparisons. P values ≤ 0.05 were taken to indicate statistical significance.
Results
No serum
The three surfactant mixtures without polymer (lipids alone, lipids with KL 4 0.4, and lipids with KL 4 0.8) performed well with respect to all measures of surface activity (Table 1) . One notable and significant difference was an increase in initial surfactant adsorption when comparing formulations with 0, 0.4 or 0.8 mg/ml KL 4 , resulting in values of 32, 25, and 20 mN/m, respectively.
When polymer was added to the lipid mixtures with or without KL 4 , only a few differences in surface activity were noted. All three surfactant mixtures had higher maximum surface tensions after 30 , p = 0.02), and A 10 increased significantly when PEG was added to lipids without KL 4 (41 vs. 27, p = 0.03).
Lipid mixtures (absent KL 4 ) with or without polymer with serum
Lipid mixtures, with or without PEG, were inhibited at the lowest serum concentration (350 µg/ml). The addition of HA (MW of either 250 or 1240 kDa) increased the threshold of inhibition to above 350 µg/ml (Tables 4 and 5; Fig. 1 ). With HA, minimum surface tension after 5 min of cycling was 8 or 9 mN/m compared to 29 mN/m without HA (p b 0.001). Other measures of surface activity also improved considerably with the addition of HA to lipid mixtures. For example, the minimum surface tension at the 10th cycle was 16 instead of 34 mN/m and the A 10 was as low as 35 compared to N47 (for both comparisons, p b 0.001). Table 2 shows six measured surface activity indices for some mixtures with KL 4 0.4. For example, minimum surface tensions after the 10th cycle and after 5 min for the 350 µg/ml serum mixture were 27 and 14 mN/m with no polymer. With HA 1240 kDa and 1400 µg/ ml serum, the values were 17 and 9 mN/m respectively. These differences were significant even though the serum concentration was four times higher for the mixture with HA (p b 0.001 for both comparisons).
KL 4 0.4 with or without polymer (serum present)
With this concentration of KL 4 without polymer, lipid mixtures were inhibited with 350 µg/ml of serum although surface activity measures were improved (but not significantly) compared to mixtures without KL 4 . With the addition of HA 250 kDa, the threshold for inhibition was between 350 and 700 µg/ml ( Table 5 ). The effect of adding PEG further increased the threshold to between 700 and 1050 µg/ml. The addition of HA 1240 kDa raised the threshold to a level greater than 1400 µg/ml serum (Fig. 2 ).
KL 4 0.8 with or without polymer (serum present)
At this concentration of KL 4 with a serum concentration of 1050 µg/ml, all mixtures with or without polymer performed well (Table 3 ). When serum was increased to 1400 µg/ml, surface activity with KL 4 was inhibited. With addition of polymer, even at this high concentration of serum, inhibition was largely prevented. With 1400 µg/ml serum, without polymer, the minimum surface tensions after the 10th cycle and after 5 min were 34 and 25 mN/m. When PEG was added, the surface tensions decreased significantly to 22 and 3 mN/m respectively (p b 0.001). With HA 1240 kDa, corresponding values were 14 and 7 mN/m (p b 0.001).
Threshold values for inhibition with serum, for all combinations of lipids, KL 4 and polymer, are summarized in Table 5 . Lipids alone or with PEG or the lower concentration of KL 4 were readily inhibited with low concentrations of serum, whereas mixtures with the higher concentration of KL 4 with polymer, were least inhibited even by high concentrations of serum.
Maximum surface tensions
The maximal surface tensions tended to be highest with 1240 kDa HA present in the mixtures, and highest in the absence of KL 4 and serum (Tables 1-4 ).
Discussion
The primary results of this study show that both KL 4 of serum. The combination of polymers and KL 4 reduces susceptibility to inhibition with serum to a greater degree than either alone, at least within the range of the concentrations studied ( Table 5 ). The addition of HA to lipids raises the inhibition threshold to more than 350 µg/ml of serum, a result superior to adding 0.4 KL 4 without polymer. Addition of polymers with the lower concentration of KL 4 improves surface activity to a greater degree than doubling the concentration of KL 4 . These results suggest (but do not prove) that the effects of KL 4 and polymers may differ and are additive. Maximal surface tensions tended to be highest in mixtures with high molecular weight HA although these mixtures had the lowest minimal surface tensions and low surface film compressibility on reduction of film surface area (decreased bubble size). Higher concentrations of KL 4 with HA tended to lower maximal surface tensions. The physiological significance of changes in maximal surface tension is less well understood than changes in minimal surface tension. Maximal surface tension is affected by many factors such as film collapse pressure and re-spreading rates, dilatational viscosity of the surface film, diffusivity of surfactant particles in the bulk phase (and hence viscosity of the bulk phase), and other conditions. In prior work we have measured the viscosity effects of HA with surfactant mixtures under a variety of conditions [36] . KL 4 is a simple peptide that in some respects has been found to mimic the effects of SP-B when added to surfactant lipids [37] . Presumably KL 4 is not affected by the purification and reconstitution methods that may alter the function of native surfactant proteins when added to surfactant lipids. Whether additive effects between peptide and polymer as we have found in this study also occur with native SP-B is under current investigation.
peptide and polymers improve surface activity of surfactant lipids in the presence
SP-A and SP-B have long been known to enhance surfactant surface adsorption and to maintain surface activity in the presence of some inhibitors [20, 38, 39] . Hall and others have shown that SP-B catalyzes the transformation of the surfactant bilayer in the subphase to a monolayer at the air-surface interface, allowing surfactant to alter surface tension [18, 40] . Whether both effects (enhanced adsorption and decreased inhibition) occur by a similar mechanism is not known.
HA and PEG have a variety of attributes that may be critical for reducing surfactant inhibition by serum. Both have a high affinity for binding water. HA has the highest water binding capacity and also has the ability to self-aggregate. These properties may segregate inhibitors from surfactant components. While HA binds to various proteins, to date there is no report of specific HA-surfactant protein interactions.
On the other hand HA has been found to bind to simple lipids [41] and affect lipid structure [42] [43] . When HAs of 170, 740, and 1900 kDa are mixed with DPPC or egg lecithin, electron microscopy reveals aggregates and sheets of lipids in contrast to the vesicular forms seen in the absence of HA [44] . The formation of these aggregates may affect surfactant adsorption.
PEG also has the ability to aggregate lipids [45, 46] . The enhanced adsorption of surfactant-polymer mixtures in the presence serum inhibition can also be explained using a depletion attraction model [47] [48] [49] [50] . Large surfactant aggregates are pushed towards each other and the interface by an osmotic pressure induced by the exclusion ("depletion") of the polymer from the space between the surfactant aggregates and the interface. This depletion attraction is sufficiently strong that it can overcome (to a degree) the electrostatic and steric repulsion imposed by serum proteins adsorbed on the interface. The increased surfactant adsorption helps to drive the serum from the interface, resulting in a reversal of the inactivation. The charge carried by HA may explain why HA can reduce inhibition at lower weight fractions than the neutral, lower molecular weight polymer, PEG [48] .
The relevance of in vitro results to possible effects that may occur in the vastly more complex lung is always problematic. Because of the limitations of our assay, we used much lower concentrations of surfactant and total serum protein than found in injured lungs. The best estimates of alveolar fluid protein concentrations are from Ishizaka et al. [51] . They find about 25 mg albumin/ml of undiluted alveolar fluid in ARDS patients vs. 5 mg/ml for volunteers with healthy lungs. Since estimates of surfactant concentrations in the lung of ARDS patients are slightly reduced from normal, we assume a surfactant concentration in situ of 20-70 mg/ml, which would imply a protein to surfactant ratio of approximately 1:1 to 1:3 (w/w) in patients with ARDS. For our measurements of surface activity, we are using a maximal serum protein concentration of 1.4 mg protein to 1.25 mg surfactant, which is roughly the ratio that we estimate above for patients with ARDS. In general, results reported here are consistent with our previous findings when polymers are added to various therapeutic surfactants (isolated from cow, calf, or pig lung) and tested in animal models of lung injury [7, 8] .
Conclusions
Addition of polymer can substantially improve the surface activity of KL 4 surfactant mixtures in the presence of serum. Of special note is the finding that adding HA 1240 kDa to KL 4 0.4 demonstrated better surface activity than KL 4 0.8 without polymer. This result also indicates that the useful threshold for KL 4 addition to lipid mixtures can be lowered from 0.8 to 0.4 mg/ml in the presence of HA 1240 kDa. Alternatively, one could use the higher peptide level with HA 1240 kDa and achieve even greater resistance to inhibition of surface activity. PEG was also found to substantially improve surface activity when added to KL 4 mixtures presumably due to depletion forces. These results suggest that future in vivo studies using KL 4 and polymer are warranted and may lead to new surfactant formulations that may be effective in diseases with significant protein leak into alveolar spaces. These new synthetic peptide-polymer surfactants would have the advantages of increased reproducibility, improved safety, and possibly reduced cost.
